Top

BMC Cancer

Published in:

01-12-2021 | Colon Cancer | Research article

Association of chemotherapy with survival in stage II colon cancer patients who received radical surgery: a retrospective cohort study

Authors: Zhihao Lv, Yuqi Liang, Huaxi Liu, Delong Mo

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

It remains controversial whether patients with Stage II colon cancer would benefit from chemotherapy after radical surgery. This study aims to assess the real effectiveness of chemotherapy in patients with stage II colon cancer undergoing radical surgery and to construct survival prediction models to predict the survival benefits of chemotherapy.

Methods

Data for stage II colon cancer patients with radical surgery were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (1:1) was performed according to receive or not receive chemotherapy. Competitive risk regression models were used to assess colon cancer cause-specific death (CSD) and non-colon cancer cause-specific death (NCSD). Survival prediction nomograms were constructed to predict overall survival (OS) and colon cancer cause-specific survival (CSS). The predictive abilities of the constructed models were evaluated by the concordance indexes (C-indexes) and calibration curves.

Results

A total of 25,110 patients were identified, 21.7% received chemotherapy, and 78.3% were without chemotherapy. A total of 10,916 patients were extracted after propensity score matching. The estimated 3-year overall survival rates of chemotherapy were 0.7% higher than non- chemotherapy. The estimated 5-year and 10-year overall survival rates of non-chemotherapy were 1.3 and 2.1% higher than chemotherapy, respectively. Survival prediction models showed good discrimination (the C-indexes between 0.582 and 0.757) and excellent calibration.

Conclusions

Chemotherapy improves the short-term (43 months) survival benefit of stage II colon cancer patients who received radical surgery. Survival prediction models can be used to predict OS and CSS of patients receiving chemotherapy as well as OS and CSS of patients not receiving chemotherapy and to make individualized treatment recommendations for stage II colon cancer patients who received radical surgery.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590.CrossRefPubMed

Jessup JM, Menck HR, Winchester DP, Hundahl SA, Murphy GP. The National Cancer Data Base report on patterns of hospital reporting. Cancer. 1996;78(8):1829–37. https://doi.org/10.1002/(sici)1097-0142(19961015)78:8<1829:aid-cncr26>3.0.co;2-z.CrossRefPubMed

O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American joint committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96(19):1420–5. https://doi.org/10.1093/jnci/djh275.CrossRefPubMed

Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394(10207):1467–80. https://doi.org/10.1016/s0140-6736(19)32319-0.CrossRefPubMed

Benson AB 3rd, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408–19. https://doi.org/10.1200/JCO.2004.05.063.CrossRefPubMed

Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24 Suppl 6:vi64-72. 2013. https://doi.org/10.1093/annonc/mdt354.

Casadaban L, Rauscher G, Aklilu M, Villenes D, Freels S, Maker AV. Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer. Cancer. 2016;122(21):3277–87. https://doi.org/10.1002/cncr.30181.CrossRefPubMed

Simillis C, Singh H, Afxentiou T, et al. Postoperative chemotherapy improves survival in patients with resected high-risk stage II colorectal cancer: results of a systematic review and meta-analysis. Color Dis. 2020;22(10):1231–44. https://doi.org/10.1111/codi.14994.CrossRef

Matsuda C, Ishiguro M, Teramukai S, Kajiwara Y, Fujii S, Kinugasa Y, Nakamoto Y, Kotake M, Sakamoto Y, Kurachi K, Maeda A, Komori K, Tomita N, Shimada Y, Takahashi K, Kotake K, Watanabe M, Mochizuki H, Nakagawa Y, Sugihara K, SACURA Study Group. A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial. Eur J Cancer. 2018;96:54–63. https://doi.org/10.1016/j.ejca.2018.03.009.CrossRefPubMed

10.

Booth CM, Nanji S, Wei X, Peng Y, Biagi JJ, Hanna TP, Krzyzanowska MK, Mackillop WJ. Adjuvant chemotherapy for stage II Colon Cancer: practice patterns and effectiveness in the general population. Clin Oncol. 2017;29(1):e29–38. https://doi.org/10.1016/j.clon.2016.09.001.CrossRef

11.

Agha R, Abdall-Razak A, Crossley E, Dowlut N, Iosifidis C, Mathew G, Beamishaj, Bashashati M, Millham FH, Orgill DP, Noureldin A, Nixon IJ, Alsawadi A, Bradley PJ, Giordano S, Laskin DM, Basu S, Johnston M, Muensterer OJ, Mukherjee I, Ngu JCY, Valmasoni M, Pagano D, Vasudevan B, Rosin RD, McCaul JA, Albrecht J, Hoffman JR, Thorat MA, Massarut S, Thoma A, Kirshtein B, Afifi RY, Farooq N, Challacombe B, Pai PS, Perakath B, Kadioglu H, Aronson JK, Raveendran K, Machado-Aranda D, Klappenbach R, Healy D, Miguel D, Leles CR, Ather MH. STROCSS 2019 guideline: strengthening the reporting of cohort studies in surgery. Int J Surg. 2019;72:156–65. https://doi.org/10.1016/j.ijsu.2019.11.002.CrossRefPubMed

12.

Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9. https://doi.org/10.1158/1078-0432.CCR-04-0713.CrossRefPubMed

13.

Noone AM, Lund JL, Mariotto A, Cronin K, McNeel T, Deapen D, Warren JL. Comparison of SEER treatment data with Medicare claims. Med Care. 2016;54(9):e55–64. https://doi.org/10.1097/mlr.0000000000000073.CrossRefPubMedPubMedCentral

14.

Zhou Z, Mo S, Dai W, Xiang W, Han L, Li Q, Wang R, Liu L, Zhang L, Cai S, Cai G. Prognostic nomograms for predicting cause-specific survival and overall survival of stage I-III colon cancer patients: a large population-based study. Cancer Cell Int. 2019;19(1):355. https://doi.org/10.1186/s12935-019-1079-4.CrossRefPubMedPubMedCentral

15.

Liu J, Huang X, Yang W, Li C, Li Z, Zhang C, Chen S, Wu G, Xie W, Wei C, Tian C, Huang L, Jeen F, Mo X, Tang W. Nomogram for predicting overall survival in stage II-III colorectal cancer. Cancer Med. 2020;9(7):2363–71. https://doi.org/10.1002/cam4.2896.CrossRefPubMedPubMedCentral

16.

Wang Y, Wu J, He H, Ma H, Hu L, Wen J, Lyu J. Nomogram predicting cancer-specific mortality in early-onset rectal cancer: a competing risk analysis. Int J Color Dis. 2020;35(5):795–804. https://doi.org/10.1007/s00384-020-03527-9.CrossRef

17.

Zheng P, Lai C, Yang W, Guo J, Xiao S, Chen Z. Nomogram predicting cancer-specific survival in elderly patients with stages I-III colon cancer. Scand J Gastroenterol. 2020;55(2):202–8. https://doi.org/10.1080/00365521.2020.1720280.CrossRefPubMed

18.

Fu J, Wu L, Ge C, Xu T, Li D, Fu W, Wang L, du J. De-escalating chemotherapy for stage II colon cancer? Ther Adv Gastroenterol. 2019;12:1756284819867553. https://doi.org/10.1177/1756284819867553.CrossRef

19.

O’Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011;29(25):3381–8. https://doi.org/10.1200/JCO.2010.34.3426.CrossRefPubMedPubMedCentral

20.

Group QC. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020–9. https://doi.org/10.1016/S0140-6736(07)61866-2.CrossRef

21.

Labianca R, Pancera G, Torri V, Zaniboni A, Erlich-man CMS. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International multicentre pooled analysis of Colon Cancer trials (IMPACT) investigators. Lancet. 1995;345:939–44.CrossRef

22.

Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1–42. https://doi.org/10.1007/s10147-019-01485-z.CrossRefPubMed

23.

Benson 3rd AB, Venook AP, Cederquist L, et al (2017) Colon Cancer, Version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 15:370–398. https://doi.org/10.6004/jnccn.2017.0036, 3.

24.

Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23(10):2479–516. https://doi.org/10.1093/annonc/mds236.CrossRefPubMed

25.

Shah MA, Renfro LA, Allegra CJ, André T, de Gramont A, Schmoll HJ, Haller DG, Alberts SR, Yothers G, Sargent DJ. Impact of patient factors on recurrence risk and time dependency of Oxaliplatin benefit in patients with Colon Cancer: analysis from modern-era adjuvant studies in the adjuvant Colon Cancer end points (ACCENT) database. J Clin Oncol. 2016;34(8):843–53. https://doi.org/10.1200/jco.2015.63.0558.CrossRefPubMedPubMedCentral

26.

Andre T, de Gramont A, Vernerey D, et al. Adjuvant fluorouracil, Leucovorin, and Oxaliplatin in stage II to III Colon Cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol. 2015;33(35):4176–87. https://doi.org/10.1200/JCO.2015.63.4238.CrossRefPubMed

27.

Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, Qian ZR, Morikawa T, Shen J, Meyerhardt JA, Fuchs CS, Ogino S. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013;105(15):1151–6. https://doi.org/10.1093/jnci/djt173.CrossRefPubMedPubMedCentral

Title: Association of chemotherapy with survival in stage II colon cancer patients who received radical surgery: a retrospective cohort study
Authors: Zhihao Lv
Yuqi Liang
Huaxi Liu
Delong Mo
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Colon Cancer
Colon Cancer
Cytostatic Therapy
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08057-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Nivolumab plus ipilimumab versus nivolumab in individuals with treatment-naive programmed death-ligand 1 positive metastatic soft tissue sarcomas: a multicentre retrospective study

Survival of colorectal cancer patients in Brunei Darussalam: comparison between 2002–09 and 2010–17

Robot-assisted thoracic surgery versus video-assisted thoracic surgery for lung lobectomy or segmentectomy in patients with non-small cell lung cancer: a meta-analysis

Risk and prognostic factors of breast cancer with liver metastases

MMP1 and MMP9 are potential prognostic biomarkers and targets for uveal melanoma

Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer